138 related articles for article (PubMed ID: 33039483)
21. Pulsed-dye laser as an adjuvant treatment for papulopustular eruptions from epidermal growth factor receptor inhibitors, a randomized blinded split-faced controlled trial.
Rerknimitr P; Suphankong Y; Panchaprateep R; Kerr SJ; Asawanonda P
Lasers Surg Med; 2019 Sep; 51(7):584-591. PubMed ID: 30843231
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
[TBL] [Abstract][Full Text] [Related]
23. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
Hsiao YW; Lin YC; Hui RC; Yang CH
J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
[No Abstract] [Full Text] [Related]
24. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
25. A painful rash after chemotherapy.
Ching S; Lam YK
Eur J Intern Med; 2019 Jun; 64():e7. PubMed ID: 30617017
[No Abstract] [Full Text] [Related]
26. Erlotinib-induced pustular eruption.
Cusano F; Ferrara G; Barletta E; Ingordo V
G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis.
He C; Lin R; Zhang J; Sun L; Lin J; Lin L
Medicine (Baltimore); 2021 Jan; 100(1):e23875. PubMed ID: 33429746
[TBL] [Abstract][Full Text] [Related]
28. Acneiform eruption as a probable paradoxical reaction to adalimumab.
Fernández-Crehuet P; Ruiz-Villaverde R
Int J Dermatol; 2015 Aug; 54(8):e306-8. PubMed ID: 24697221
[No Abstract] [Full Text] [Related]
29. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
30. Oral Isotretinoin for the treatment of Aripiprazol-induced acneiform rash.
Navarro-Triviño FJ; de Jaime Ruiz P; Porras Segovia A; Garrido Torres-Puchol V
Dermatol Ther; 2018 Jul; 31(4):e12637. PubMed ID: 30019366
[TBL] [Abstract][Full Text] [Related]
31. Isotretinoin-induced bilateral sacroiliitis.
Bachmeyer C; Charoud A; Turc Y; Callot V; Blum L; Aractingi S
Dermatology; 2003; 206(3):285-6. PubMed ID: 12673094
[No Abstract] [Full Text] [Related]
32. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
[No Abstract] [Full Text] [Related]
33. [Acneiform eruption from epidermal growth factor receptor inhibitors].
Martínez de Lagrán Z; Ratón JA; Lasa O; Acebo E; Díaz-Pérez JL
Actas Dermosifiliogr; 2005 Sep; 96(7):450-4. PubMed ID: 16476273
[TBL] [Abstract][Full Text] [Related]
34. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.
Recuero JK; Fitz JR; Pereira AA; Bonamigo RR
An Bras Dermatol; 2023; 98(4):429-439. PubMed ID: 36990917
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous side-effects of EGFR inhibitors and their management.
Ehmann LM; Ruzicka T; Wollenberg A
Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
[TBL] [Abstract][Full Text] [Related]
36. Facial acneiform rash associated with sorafenib.
Fleta-Asín B; Vañó-Galván S; Ledo-Rodríguez A; Truchuelo-Díez M; Jaén-Olasolo P
Dermatol Online J; 2009 Apr; 15(4):7. PubMed ID: 19450400
[TBL] [Abstract][Full Text] [Related]
37. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
38. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
39. A comedonal acneiform eruption following dovitinib therapy.
Gracia-Cazaña T; Pastushenko I; Concellón MA; Grasa-Jordán MP
Clin Exp Dermatol; 2014 Oct; 39(7):842-3. PubMed ID: 25196373
[No Abstract] [Full Text] [Related]
40. Acneiform eruptions.
Dessinioti C; Antoniou C; Katsambas A
Clin Dermatol; 2014; 32(1):24-34. PubMed ID: 24314375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
